Clinical Trial Update: Efficacy and Safety of MB-CART2019.1 vs. SoC in Lymphoma Patients [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial comparing MB-CART2019.1 CAR-T therapy to standard of care in patients with Diffuse Large B-cell Lymphoma to assess efficacy and safety;…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma

Drugs mentioned

• MB-CART2019.1

Snippet

Sponsor: Miltenyi Biomedicine GmbH | Conditions: Diffuse Large B-cell Lymphoma | Phase 2 | Status: ACTIVE_NOT_RECRUITING